Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates

Foot-and-mouth disease (FMD) is one of the most contagious veterinary viral diseases known, having economic, social and potentially devastating environmental impacts. The vaccines currently being marketed/sold around the world for disease control and prevention in bovines do not stimulate the produc...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2020
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23463
Acceso en línea:
https://doi.org/10.1016/j.vaccine.2020.04.006
https://repository.urosario.edu.co/handle/10336/23463
Palabra clave:
A24 Cruzeiro serotype
Capsid proteins
Foot-and-mouth disease virus
O1 Campos serotype
Synthetic peptide
Rights
License
Abierto (Texto Completo)
id EDOCUR2_274541abfbc94a7856bf7727abe10185
oai_identifier_str oai:repository.urosario.edu.co:10336/23463
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 16aa0ab9-4ca4-4d37-97a4-38d5544421a8-18a894743-0879-464b-9f2b-8a730acb8eaf-1bef0e283-b79d-4c95-8f32-8e35d3334e4b-1e7892a58-aac2-4c18-8e6e-7afdc3d043ba-1fc887a88-c667-4d3f-8600-d2183f4dd565-191225589-1d8d65dc1-4f4c-46b6-891e-0eee5d58adaf-14d801e15-94f5-4aef-9892-e5662b4f2ed4-199f3e956-ef2a-4251-9801-3cdd6d1ae2e2-153332dc1-6365-41c0-8bf2-a42d23dcc8fc-12bc21ca6-c67e-482d-b8de-b5561c80fb5d-151721018-122accd2d-8359-413b-b549-f20ecb6e4564-110ecd4f9-843f-4ef2-bec0-7d39d3381a13-179653065-1518948826002020-05-26T00:02:15Z2020-05-26T00:02:15Z2020Foot-and-mouth disease (FMD) is one of the most contagious veterinary viral diseases known, having economic, social and potentially devastating environmental impacts. The vaccines currently being marketed/sold around the world for disease control and prevention in bovines do not stimulate the production of antibodies having crossed reactions to different serotypes. This means that if an animal becomes infected by a serotype which has not been included in a vaccine then it will develop the disease. Synthetic peptide vaccines represent a safer option and (depending on the design) can stimulate antibodies protecting against different variants. Based on the forgoing, this work was aimed at evaluating FMDV VP1, VP2 and VP3 protein-derived, modified and chemically-synthesised peptides’ ability to induce an immune response for developing a vaccine contributing towards controlling the disease. VP1, VP2 and VP3 proteins’ conserved regions were selected for this. Peptides from these regions were chemically synthesised; binding assays were then carried out for ascertaining whether they were involved in BHK-21 cell binding. Selected peptides’ structure and location were studied. Peptides which did bind were modified and formulated with Montanide ISA 70 adjuvant; 17 animals were immunised twice with the formulation. The animals were genotyped by amplifying the BoLA-DRB3.2 gene. Blood samples were taken from 17 cattle on day 43 post-first immunisation for studying the formulation's immunogenicity. The sera were used in ELISA, immunofluorescence, flow cytometry, immunoadsorption and seroneutralisation assays. The A24 Cruzeiro and O1 Campos virus serotypes were used for these assays. The results revealed that even though protein exposure and 3D structure might be different amongst serotypes, the antibodies so produced could inhibit virus entry to cells, thereby showing the selected peptides’ in vitro protection-inducing ability. © 2020 Elsevier Ltdapplication/pdfhttps://doi.org/10.1016/j.vaccine.2020.04.0060264410X13588745https://repository.urosario.edu.co/handle/10336/23463engElsevier Ltd3951No. 233942VaccineVol. 38Vaccine, ISSN:0264410X, 13588745, Vol.38, No.23 (2020); pp. 3942-3951https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083301641&doi=10.1016%2fj.vaccine.2020.04.006&partnerID=40&md5=ff04037bef0e0b0373920c220f0a78daAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURA24 Cruzeiro serotypeCapsid proteinsFoot-and-mouth disease virusO1 Campos serotypeSynthetic peptideEvaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidatesarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Avendaño, CatalinaCelis-Giraldo, CarmenOrdoñez, DiegoRodríguez-Habibe, IbettOviedo, JairoCurtidor, HernandoGarcía-Castiblanco, SebastiánMartínez-Panqueva, FredyCamargo-Castañeda, AndreaReyes, CésarBohórquez, Michel D.Vanegas, MagnoliaCantor, DanielaPatarroyo, Manuel E.Patarroyo, Manuel A.Díaz Arévalo, Diana10336/23463oai:repository.urosario.edu.co:10336/234632022-05-02 07:37:20.986331https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
title Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
spellingShingle Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
A24 Cruzeiro serotype
Capsid proteins
Foot-and-mouth disease virus
O1 Campos serotype
Synthetic peptide
title_short Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
title_full Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
title_fullStr Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
title_full_unstemmed Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
title_sort Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates
dc.subject.keyword.spa.fl_str_mv A24 Cruzeiro serotype
Capsid proteins
Foot-and-mouth disease virus
O1 Campos serotype
Synthetic peptide
topic A24 Cruzeiro serotype
Capsid proteins
Foot-and-mouth disease virus
O1 Campos serotype
Synthetic peptide
description Foot-and-mouth disease (FMD) is one of the most contagious veterinary viral diseases known, having economic, social and potentially devastating environmental impacts. The vaccines currently being marketed/sold around the world for disease control and prevention in bovines do not stimulate the production of antibodies having crossed reactions to different serotypes. This means that if an animal becomes infected by a serotype which has not been included in a vaccine then it will develop the disease. Synthetic peptide vaccines represent a safer option and (depending on the design) can stimulate antibodies protecting against different variants. Based on the forgoing, this work was aimed at evaluating FMDV VP1, VP2 and VP3 protein-derived, modified and chemically-synthesised peptides’ ability to induce an immune response for developing a vaccine contributing towards controlling the disease. VP1, VP2 and VP3 proteins’ conserved regions were selected for this. Peptides from these regions were chemically synthesised; binding assays were then carried out for ascertaining whether they were involved in BHK-21 cell binding. Selected peptides’ structure and location were studied. Peptides which did bind were modified and formulated with Montanide ISA 70 adjuvant; 17 animals were immunised twice with the formulation. The animals were genotyped by amplifying the BoLA-DRB3.2 gene. Blood samples were taken from 17 cattle on day 43 post-first immunisation for studying the formulation's immunogenicity. The sera were used in ELISA, immunofluorescence, flow cytometry, immunoadsorption and seroneutralisation assays. The A24 Cruzeiro and O1 Campos virus serotypes were used for these assays. The results revealed that even though protein exposure and 3D structure might be different amongst serotypes, the antibodies so produced could inhibit virus entry to cells, thereby showing the selected peptides’ in vitro protection-inducing ability. © 2020 Elsevier Ltd
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-05-26T00:02:15Z
dc.date.available.none.fl_str_mv 2020-05-26T00:02:15Z
dc.date.created.spa.fl_str_mv 2020
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.vaccine.2020.04.006
dc.identifier.issn.none.fl_str_mv 0264410X
13588745
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/23463
url https://doi.org/10.1016/j.vaccine.2020.04.006
https://repository.urosario.edu.co/handle/10336/23463
identifier_str_mv 0264410X
13588745
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 3951
dc.relation.citationIssue.none.fl_str_mv No. 23
dc.relation.citationStartPage.none.fl_str_mv 3942
dc.relation.citationTitle.none.fl_str_mv Vaccine
dc.relation.citationVolume.none.fl_str_mv Vol. 38
dc.relation.ispartof.spa.fl_str_mv Vaccine, ISSN:0264410X, 13588745, Vol.38, No.23 (2020); pp. 3942-3951
dc.relation.uri.spa.fl_str_mv https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083301641&doi=10.1016%2fj.vaccine.2020.04.006&partnerID=40&md5=ff04037bef0e0b0373920c220f0a78da
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier Ltd
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167436312707072